We’re delighted to share the video and slide deck from our recent webinar featuring Dr. Dale Kempf (AbbVie), Dr. Ben Gold (Weill Cornell Medical College) and Dr. Peter Warner (Bill and Melinda Gates Foundation):
Tuberculosis (TB) is a terrible disease. Although there are first line and second line TB drugs, new medicines are urgently needed given both constantly emerging resistance, as well as the lengthy half-year regimens required for treatment.
An innovative collaboration going by the acronym TBDA (TB Drug Accelerator) is presented by AbbVie Distinguished Research Fellow Dr. Dale Kempf and Weill Cornell Medicine Associate Professor Dr. Ben Gold, moderated by the Gates Foundation Senior Program Officer Dr. Peter Warner. The TBDA brings together 7 major biopharmaceutical companies with leading academic, non-profit and government researchers to “identify new ways to target bacteria that are resistant to current drug regimens, develop new tools for drug discovery, and discover new drugs that can lead to accelerated treatments.”
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities.
CDD Vault: Drug Discovery Informatics your whole project team will embrace